American Society of Gene + Cell Therapy

ASGCT is pleased to be at the #NORDSummit this week! Stop by our booth to connect with our patient education resources (including our new coloring book!) and discuss the latest policies affecting rare disease research and individuals.

The 2026 Breakthroughs abstracts are now available! Preview the latest cell and gene therapy research ahead of #ASGCTBreakthroughs, Nov. 12-13. Register now to join the conversation in Nashville or virtually. Explore abstracts + register: https://asgct.org/breakthroughs

Next week is Epidermolysis Bullosa Awareness Week. Learn more about the different types of EB, the current and emerging CGT treatments, and more on our website: https://bit.ly/4iVmEsx.

Congratulations to the 9 ASGCT members elected to the National Academy of Medicine! @nam.edu Their pioneering research and clinical leadership continue to drive progress in cell and gene therapy and improve patient outcomes worldwide. We're proud to celebrate this outstanding achievement. #ASGCT

Hot off the press! 📢 Our Q3 2026 Gene, Cell and RNA Therapy Landscape Report, developed with Citeline, is here. Explore seven new approvals, an expanding clinical pipeline and the latest advancements shaping the field. Read more: https://bit.ly/4ufliLp #ASGCT #CGT

One month to go! Join ASGCT and CHOP on Nov. 20 for a full day focused on the safety, translation, and real-world implementation of AAV & LNP gene therapies. Gain practical insights from clinical and translational experts and earn CME credit. 🔗 https://bit.ly/4uK4PPz

This Health Literacy Awareness Month, we're celebrating the importance of helping people find, understand, and use health information to make informed decisions. Visit patienteducation.asgct.org to explore patient-friendly resources, subscribe to The Patient Press newsletter, and more.

Be part of what's next in 2027. ASGCT members are invited to renew their membership for the coming year. Not a member? It's the perfect time to join. https://bit.ly/4yvcuUq

🎙️ This month, we welcomed Bruce Levine, PhD to the podcast! In this episode, Dr. Levine talks about finding his way into immunology, learning from pivotal mentors, and following the unexpected opportunities that led him to the forefront of cell therapy. Take a listen now! https://bit.ly/4yIhFk9

On-demand access to our 2026 Policy Summit is now available! Catch up on the conversations you missed or rewatch your favorite sessions. Access on-demand now ➡️ https://www.asgct.org/events-meetings/2026-policy-summit

ASGCT and NTSAD are launching the inaugural NTSAD-ASGCT Translational Research Fellowship Program to help advance innovative genetic medicine research for rare neurogenetic diseases. Learn more about the fellowship, eligibility criteria and application deadlines: https://bit.ly/4hciETk

Join the 2026 NORD Breakthrough Summit, Oct. 25–27 in Washington, D.C.! ASGCT staff will be there to connect you with patient education resources and discuss the latest policies affecting rare disease research and individuals. Learn more ➡️ nordsummit.org #NORDSummit #RareDisease

🔬 Don't wait for the Annual Meeting to share your latest science! Submit your late-breaking abstract for Breakthroughs in Cell + Gene Therapy by Monday, October 12, 2026. Learn more and submit now ➡️ https://bit.ly/4wHH10l

Submit an abstract to the Inaugural Canadian Gene and Cell Therapy Conference by October 1! For more information or to submit an abstract, visit cancgt.ca.

📢 We're less than one week away from the 2026 Policy Summit! Register now ➡️ https://bit.ly/4wIMIem #ASGCTadvocacy #PS26

The FDA has approved Genglycos, an AAV gene therapy developed by Ultragenyx Pharmaceuticals. Read our full blog post about the approval here: https://bit.ly/3SbpDlN

📰 Our latest edition of The Patient Press newsletter is now available! This month, read updates about OMB, check out our two new Patient Education resources, catch up on our recent Congressional Briefing on CGT for Rare Disease, and more. Read The Patient Press now ➡️ https://bit.ly/4il1BiC

🎙️ Meet Anna Maurer, PhD in our newest episode of Scientists, Unedited. Recorded live at the 2026 Annual Meeting in Boston, host Eirini Vamva, PhD talks with Dr. Maurer about growing up in Michigan, studying at Harvard Medical School, and her work in AAV. Listen now! ➡️ https://bit.ly/44O6hpt

Hear from leading minds in oncology at this fully virtual event! Join us Oct 14-15 to learn about the innovative approaches reshaping cancer treatment while addressing the critical challenges currently facing the field. Register now ➡️ https://bit.ly/4aX9OVW

From blood cancers to autoimmune diseases, CAR T-cell therapy is expanding far beyond its original boundaries. Start learning in our latest content collection: https://learning.asgct.org/courses/238146

A new stage for Breakthroughs: Join us in Nashville! Customize your experience across three concurrent tracks covering translation & manufacturing, biological precision, and the new therapeutic architectures overcoming challenges in the central nervous system: asgct.org/breakthroughs

ASGCT's advocacy on OMB's proposed Uniform Guidance reforms continues. This month, the Society submitted comments urging OMB to withdraw the rule, led a coalition letter to Congress, and launched grassroots outreach to protect #CGT research. Read more: https://bit.ly/4voQvvR #ASGCTAdvocacy

Fyodor Urnov, 2026 ASGCT Catalyst Award co-recipient, joins this episode of The Issue to discuss the rapid evolution of gene-editing technology and the critical role of industry-wide collaboration in bringing life-changing therapies to patients. 🎧 Listen: https://bit.ly/4h8nDob

How is innovation advancing cell and gene therapy manufacturing? Read our #ASGCT2026 recap on how automation, analytics, and regulatory readiness are shaping the future of CGT development: https://bit.ly/4aXWNLV

Level up your cell and gene therapy experience in just one day! Dive into real-world applications of AAV, CAR T, and HSC modalities, clinical management of toxicities, and the future of individualized medicine at this focused, one-day event at @nationwidekids.bsky.social! Details: asgct.org/gme

Looking for a community that supports your career and keeps you connected to the latest in the field? Join ASGCT this summer and save up to 15% on your dues! asgct.org/become-a-member

These $100K awards provide vital financial and professional development support to postdoctoral or early-career members from groups that have historically faced limited access to research opportunities, mentorship, or career advancement resources in science. asgct.org/expanding

FDA approved Tregzi, an allogeneic cell therapy using Tregs to reduce complications of allo-HSCTs. This approval is an important advancement for patients with blood cancers. ASGCT President Dr. Matt Porteus shares what this approval means for the #CGT field: https://bit.ly/44RGgW0

The ASGCT Policy Summit is uniquely designed to break down silos and spark real collaboration with the stakeholders driving the future of cell and gene therapy policy. Join us September 14 in Washington, D.C., or online: asgct.org/policysummit

Recorded live at #ASGCT2026, listen as Molecular Therapy Advances Editor-in-Chief Dr. Mohamed Abou-el-Enein sits down with Drs. Jennifer Adair, Claire Booth, Terence Flotte, and Donald Kohn to discuss the evolving landscape of rare disease therapies: https://bit.ly/4v6eHDj

Applications are open for the ASGCT Career Development Awards, offering vital financial support to early-career scientists and postdocs driving innovation in the field. Don't miss the chance to fund your research and grow your network. Apply today: asgct.org/cda

The latest Patient Press is here! Catch up on crucial updates on proposed federal grant changes, our brand-new cell and gene therapy coloring book, a new Community Quick Take, and the latest clinical trial breakthroughs in rare disease research. https://bit.ly/4gdItSK

Biomedical innovation depends on stable research funding. We're leading a sign-on letter opposing proposed OMB changes that could slow progress in #CGTs. Organizations can sign by July 15 at 12 p.m. ET. 🔗 Sign here: https://bit.ly/4gdQ8AA

FDA approval is only the first step in bringing cell and gene therapies to patients. At #ASGCT2026, experts explored the challenges that continue to limit patient access and how value-based payment models and cross-sector collaboration can help build more sustainable pathways. https://bit.ly/4yciBNR

As we kick off our 2027 awards cycle, we invite you to take a moment to nominate your colleagues, mentors, mentees, and fellow collaborators for an ASGCT Honorific Award! https://bit.ly/4aE0A0L

What does the path to leadership in cell and gene therapy look like? Scientists, Unedited host Eirini Vamva, PhD, sits down with ASGCT President Matthew Porteus, PhD, for a candid conversation about his journey, motivations, and life beyond the lab. 🎧 Listen: https://bit.ly/4uZYFea

In rare disease research, traditional clinical trials aren't always possible. Check out this Community Quick Take to learn how patient data is helping researchers go beyond the placebo control and accelerate life-changing treatments. ▶️ Watch now: https://bit.ly/4fLiguF

📢 Registration and abstract submissions are officially open for Breakthroughs in Cell & Gene Therapy! Explore our 2026 program tracks, view abstract categories, and secure your spot today: asgct.org/breakthroughs

From dreaming about genetics since high school in Nigeria to tackling the field's biggest immune challenges as a University of Missouri PhD candidate, Godwin Iroanya's journey is all about making the "impossible" possible. Listen now: https://bit.ly/4ewfqaB

#WorldSickleCellDay reminds us of the critical importance of advancing awareness, fostering connection, and driving equitable progress for every individual and family impacted by SCD. ❤️ Hear from sickle cell warriors in this session from the 2026 Empowering Patients Summit: https://bit.ly/4os6ojo

How are patient-centered approaches shaping the future of cell and gene therapy development? Check out the key takeaways from our recent Annual Meeting symposia on aligning patient experience, regulatory strategy, and clinical trial design. Read the full recap: https://bit.ly/4vKIt18

Bringing a cell or gene therapy from concept to patient requires more than great science. The 2026 ASGCT Policy Summit dives into the full arc of CGT development, from pipeline funding and regulatory strategy through manufacturing, payment policy, and patient access. Join us:: asgct.org/policysummit

Get to know the new co-hosts, Jason West, PhD, and Sanjay D’Souza, PhD, as they share their backgrounds, ask each other questions, and share how listeners can get involved with future content of The Issue podcast. 🎧 Listen now: https://bit.ly/4vUjSXA

OMB has proposed significant changes to the federal grantmaking framework, including provisions affecting peer review, international collaboration, and scientific communication. Read more in the latest Advocate: https://bit.ly/4vzU1op #ResearchFunding #CGT #ASGCTAdvocacy

While AAV and LNPs continue to revolutionize the field, translating these powerful delivery platforms into safe, predictable, and scalable clinical therapies presents unique challenges. We're partnering with @childrensphila.bsky.social for this comprehensive, one-day event: https://bit.ly/4uK4PPz

How has ASGCT membership shaped a career in regulatory policy? Hear from Dylan Bechtle, Director of Regulatory Policy at Johnson & Johnson, on how the ASGCT community and resources have been invaluable for navigating the fast-moving cell and gene therapy space. 🎧 Listen now: https://bit.ly/3Q0zvxG

It's never been easier to start building your foundational knowledge of CGT! Our Foundations of Cell & Gene Therapy online course is: ✔️ 100% free ✔️ Entirely self-paced ✔️ Led by field experts Choose a module and start learning today: https://bit.ly/4tmnsIK

Proposed federal grant rule changes could affect how CGT research is reviewed, funded, and managed – including new limits on conference attendance, publication expenses, and international collaborations. Learn what's proposed and how to weigh in: https://bit.ly/4vusiou #ASGCTAdvocacy

Designed specifically for the next generation of medical leaders, this focused, one-day program provides the critical insights needed to navigate the rapidly evolving clinical landscape of cell and gene therapies. Learn more and register: asgct.org/gme

Our premier policy event is returning to Washington, D.C.! Join us on September 14 to connect directly with key decision-makers, advocate for the field, and drive the critical conversations shaping the future of cell and gene therapy. Secure your spot today: asgct.org/policysummit